about
Ubiquitous amyloidsMultitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies.Hexahydrochromeno[4,3-b]pyrrole derivatives as acetylcholinesterase inhibitors.Studies on the photostability and in vitro phototoxicity of Labetalol.Analysis of human histone H4 by capillary electrophoresis in a pullulan-coated capillary, LC-ESI-MS and MALDI-TOF-MS.Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238.The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?Two-carbon bridge substituted cocaines: enantioselective synthesis, attribution of the absolute configuration and biological activity of novel 6- and 7-methoxylated cocaines.Novel huprine derivatives with inhibitory activity toward β-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates.Kinetic characterization of amyloid-beta 1-42 aggregation with a multimethodological approach.A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.Human recombinant beta-secretase immobilized enzyme reactor for fast hits' selection and characterization from a virtual screening library.Design, synthesis and biological evaluation of ambenonium derivatives as AChE inhibitors.Fluorescence biosensing micropatterned surfaces based on immobilized human acetylcholinesterase.Disclosure of a fundamental clue for the elucidation of the myricetin mechanism of action as amyloid aggregation inhibitor by mass spectrometry.Mass spectrometry as an efficient tool for the characterization of amyloid β peptide 25-35 self-assembly species in aggregation and inhibition studies.Fluorinated benzophenone derivatives: balanced multipotent agents for Alzheimer's disease.Multitarget Strategy to Address Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and Computational Studies of Coumarin-Based Derivatives.Heterocyclic inhibitors of AChE acylation and peripheral sites.Protein flexibility in virtual screening: the BACE-1 case studyImmobilized butyrylcholinesterase in the characterization of new inhibitors that could ease Alzheimer's diseaseStrategies for the inhibition of protein aggregation in human diseases.Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors.Analysis of ACE inhibitors in pharmaceutical dosage forms by derivative UV spectroscopy and liquid chromatography (HPLC).Novel 8-Hydroxyquinoline Derivatives as Multitarget Compounds for the Treatment of Alzheimer's Disease.Nature-Inspired Multifunctional Ligands: Focusing on Amyloid-Based Molecular Mechanisms of Alzheimer's Disease.Disease-modifying anti-Alzheimer's drugs: inhibitors of human cholinesterases interfering with β-amyloid aggregation.2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents.Chemical and pharmacological studies on enantiomerically pure p-methoxytacripyrines, promising multi-target-directed ligands for the treatment of Alzheimer's disease.Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease.A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimer's and Prion DiseasesMultifunctional cholinesterase and amyloid Beta fibrillization modulators. Synthesis and biological investigation.Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks.Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.Structural characterization of p53 isoforms due to the polymorphism at codon 72 by mass spectrometry and circular dichroism.Benzofuran-based hybrid compounds for the inhibition of cholinesterase activity, beta amyloid aggregation, and abeta neurotoxicity.Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease.Histone proteins determined in a human colon cancer by high-performance liquid chromatography and mass spectrometry.Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.
P50
Q27016014-27C0047D-BCFE-46D4-BF74-1CEFD5C7085BQ27695652-4AD4FF6D-0CC2-4F48-B0E5-F8DA55073B1AQ30726042-0F36A6EF-58D3-4C94-AE74-0125C7DE26A5Q31805263-88BF9A90-9A76-4688-87E6-1BFC721FB64AQ32079890-AD82BC70-0C89-4BD0-A47A-B4A4C3FFDE0EQ33319847-8DA8FC1E-DFC0-4297-A8E0-5A135F769D3DQ33532912-F9DC86B7-4DC8-4D3D-A941-AF9D66D67DA9Q33630562-D1C02135-8F4C-49DE-92B1-F43F3BF3645AQ33694237-AA9ED9A2-AC80-4376-90CC-21D0AE8D7AB9Q33699095-A40BE2AB-EEC9-464D-8C1A-5C6C4BBA6A5BQ33855016-45A036F6-9713-4299-843D-FED4AB0C6DA4Q34114869-DFC7CFAA-B5A3-4226-B745-13A63571585EQ34232241-4C72A402-4615-4A2C-BC5D-6D90661CA7BAQ34246966-1651E844-F00A-4373-8484-2DF4598DBBE6Q34344371-B02F8722-6C01-4891-80A8-64174DA7D479Q34409540-4A9683D3-14E5-4774-8A8F-05669325B8AAQ35078911-8AB4C311-7910-4CB3-8A85-D50D279C633AQ35135072-D71E1974-2D76-41D7-AC07-6D3B9EA3B546Q35823536-D440CBC5-4CFF-4696-AFDB-5C8620B44CDCQ36119068-89F8BF1B-68D9-4C6A-B325-A349BE93124BQ36470957-5F2B8A5F-FEC2-4BB5-B38F-5CD289451C4BQ37122955-F65C79E4-8A99-4262-BECB-D034B4FD5F6AQ37733418-D872AD03-44D4-4C89-A837-395D373A8A89Q37866692-CD2EC5DA-9214-43CA-B1A2-94465E47343CQ38551965-DB3022D6-3B5F-4428-99E3-4CC5D0FF2FAAQ38793949-CB35CB21-3AB6-431F-9291-9DF82F0D8682Q38825382-EA96313F-5479-4BA5-84DF-8744ABBD7A52Q38984017-F6326ED1-67F4-4C3C-872A-A6921D21596EQ39242493-7B9F079A-AA2D-4AEE-851F-3C0BF4B4B976Q39459684-5581E1DF-6594-4598-ADAA-C123A3F8385DQ39472542-624AAAB5-178E-44E3-98CD-50DCED884109Q39768868-3835993F-786D-4D3E-B6C4-933741040F44Q39778610-CFF61682-AA8A-474E-80F2-CB5DFA37F249Q39790009-425B5939-E5AF-4279-8886-6CD2AF77748CQ39859798-76729616-F0C3-47A9-9459-B3797157F70BQ39878603-AE73C3DC-6771-4B6F-8D45-59C35C7B05EAQ39991065-A61D2585-B1E8-454B-833A-E7171C8B6044Q40082083-332406DF-B167-4139-9B3B-D45BAB9931E7Q40248123-4F996D7A-F2FD-4ECB-B233-401A7DDFE07AQ40352789-25CDE5E8-DD64-4106-954C-FE82ECC54E3E
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vincenza Andrisano
@ast
Vincenza Andrisano
@en
Vincenza Andrisano
@es
Vincenza Andrisano
@nl
type
label
Vincenza Andrisano
@ast
Vincenza Andrisano
@en
Vincenza Andrisano
@es
Vincenza Andrisano
@nl
prefLabel
Vincenza Andrisano
@ast
Vincenza Andrisano
@en
Vincenza Andrisano
@es
Vincenza Andrisano
@nl
P106
P1153
7006871746
P21
P31
P496
0000-0003-4396-1904